Outcomes of Immune-Checkpoint Inhibitor Rechallenge in Metastatic Clear-Cell Renal Cell Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract
Despite the negative results of the prospective randomized trials CONTACT-03 and TiNivo-2, the lack of specific stratification based on the interval between ICI exposures represents a critical gap, raising the question of whether temporal dynamics may influence response to subsequent immunotherapy. We hypothesized that longer inter-treatment intervals could be associated with improved clinical outcomes.
In this global real-world study, we leveraged the TriNetX database to evaluate outcomes in patients with mccRCC who received at least two lines of ICI-based therapy between 2016 and 2024. Among 6,737 patients, 288 (4.3%) underwent ICI rechallenge, reflecting the infrequent use of ICI rechallenge in routine clinical practice.
The most common sequencing strategies involved nivolumab- or pembrolizumab-based regimens administered across different lines of therapy. Overall, ICI rechallenge was associated with a median progression-free survival (PFS) of 8.5 months and a median overall survival (OS) of 33.2 months.
Notably, the interval between ICI exposures emerged as a key determinant of outcomes: patients rechallenged ≥6 months after prior ICI discontinuation experienced significantly improved PFS and OS compared with shorter intervals.
These findings suggest that ICI rechallenge may retain clinically meaningful activity in selected patients with mccRCC, particularly when administered after a sufficient treatment-free interval. The observed time-dependent effect supports the hypothesis that delayed rechallenge may allow partial restoration of immune competence and reprogramming of tumor–immune interactions, thereby enhancing sensitivity to renewed PD-1/PD-L1 blockade.
Although limited by its retrospective design, this analysis represents one of the largest real-world evaluations of ICI rechallenge in renal cell carcinoma. These findings support prospective studies aimed at optimizing treatment sequencing, refining the role of timing, and identifying biomarkers to better select patients most likely to benefit from immunotherapy rechallenge.
Written by: Antonio Cigliola, MD, Genitourinary Medical Oncologist, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
Read the Abstract